Valganciclovir Hydrochloride (CAS 175865-59-5): Potent Antiviral for CMV and Transplant Patients
Discover Valganciclovir Hydrochloride, a vital antiviral compound offering effective treatment and prevention for CMV infections, enhancing patient outcomes globally.
Get a Quote & SampleProduct Core Value: Advanced Antiviral Solutions
Valganciclovir Hydrochloride
Valganciclovir Hydrochloride stands as a cornerstone in antiviral therapy, particularly as a prodrug of ganciclovir. Its superior oral bioavailability makes it an indispensable agent in the fight against Cytomegalovirus (CMV) infections, offering a more convenient and effective treatment option for patients. This high-purity compound plays a crucial role in improving the quality of life for immunocompromised individuals.
- Unrivaled efficacy for CMV retinitis treatment: Valganciclovir Hydrochloride is specifically designed to combat CMV retinitis, a severe eye infection often found in immunocompromised patients, ensuring clearer vision and infection control.
- Essential in organ transplant prophylaxis: As a critical element in post-transplant care, Valganciclovir ensures effective prevention of CMV disease in organ transplant recipients, significantly reducing complication risks.
- High purity and reliability as an API: Our Valganciclovir Hydrochloride boasts high purity (≥98%), making it a reliable active pharmaceutical ingredient for various medical formulations worldwide.
- Strategic advantage as a ganciclovir prodrug: The prodrug design of Valganciclovir enhances its absorption and systemic exposure, delivering ganciclovir effectively where it's needed most to inhibit viral DNA polymerase.
Key Advantages
Potent Antiviral Action
Valganciclovir Hydrochloride exhibits powerful antiviral activity by effectively converting to ganciclovir, which inhibits viral DNA polymerase and halts CMV replication, offering a robust solution for CMV treatment.
Enhanced Bioavailability
Its prodrug nature ensures improved oral bioavailability compared to ganciclovir, leading to more predictable drug levels and superior therapeutic outcomes, especially beneficial for Valganciclovir dosage for CMV management.
Reliable Quality and Supply
As a leading Valganciclovir Hydrochloride manufacturer, we ensure consistent high quality and a steady supply, meeting the demands of global pharmaceutical markets and supporting critical healthcare needs.
Key Applications
CMV Retinitis Treatment
Valganciclovir Hydrochloride is a frontline medication for treating CMV retinitis, providing a potent defense against vision-threatening infections in immunocompromised patients and improving ocular health.
Organ Transplant Prophylaxis
Crucially, Valganciclovir is widely used for Valganciclovir organ transplant prophylaxis, preventing CMV disease in kidney, heart, and kidney-pancreas transplant recipients, safeguarding their recovery.
Active Pharmaceutical Ingredient
As a high-quality Valganciclovir API, it serves as a foundational component for pharmaceutical manufacturers, ensuring the efficacy and safety of finished drug products globally.
Antiviral Research and Development
The unique Valganciclovir mechanism of action makes it a subject of continuous research, contributing to advancements in antiviral therapy and drug discovery, especially in complex viral infections.